期刊
JOURNAL OF CLINICAL MEDICINE
卷 8, 期 11, 页码 -出版社
MDPI
DOI: 10.3390/jcm8111893
关键词
Alzheimer's disease; amnestic mild cognitive impairment; plasma biomarkers; immunomagnetic reduction
资金
- Ministry of Science and Technology of Taiwan [MOST 105-2314-B-016-004-, MOST 106-2314-B-016-007-MY2, MOST 108-2314-B-016-020-, MOST 108-2314-B-016-023-]
- TSGH [TSGH-C101-159, TSGH-C106-068, TSGH-C108-100, TSGH-C108-216]
Brain degeneration in patients with Alzheimer's disease (AD) results from the accumulation of pathological amyloid-beta (A beta) plaques and tau protein tangles, leading to altered plasma levels of biomarkers. However, few studies have investigated the association between plasma biomarkers and cognitive impairment in patients with AD. In this cross-sectional study, we investigated correlations between mini-mental state examination (MMSE) scores and levels of plasma biomarkers in patients with amnestic mild cognitive impairment (aMCI) and AD. Thirteen individuals with normal cognition, 40 patients with aMCI, and 37 patients with AD were enrolled. Immunomagnetic reduction was used to assess the levels of plasma biomarkers, including amyloid A beta(1-40), A beta(1-42), total tau protein (t-Tau), and phosphorylated tau protein (threonine 181, p-Tau181). Our analysis revealed a significant negative correlation between MMSE and both measures of tau, and a trend toward negative correlation between MMSE and A beta(1-42). In a longitudinal study involving three patients with aMCI and two patients with AD, we observed strong negative correlations (r < -0.8) between changes in MMSE scores and plasma levels of t-Tau. Our results suggest that plasma levels of t-Tau and p-Tau181 can be used to assess the severity of cognitive impairment in patients with AD. Furthermore, the results of our preliminary longitudinal study suggest that levels of t-Tau can be used to monitor the progression of cognitive decline in patients with aMCI/AD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据